Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
MBX Biosciences, Inc. (MBX) had Consolidated Net Income/Loss of $-21.62M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-21.62M |
|
-- |
|
-- |
|
$23.93M |
|
$-23.93M |
|
$2.31M |
|
$-21.62M |
|
$-21.62M |
|
$-21.62M |
|
$-21.62M |
|
|
Consolidated Net Income/Loss |
$-21.62M |
$-21.62M |
|
$-23.93M |
|
$-23.88M |
|
34.20M |
|
34.20M |
|
$-0.63 |
|
$-0.63 |
|
| Balance Sheet Financials | |
$397.50M |
|
$2.00M |
|
$2.57M |
|
$400.08M |
|
$12.06M |
|
-- |
|
$0.48M |
|
$12.54M |
|
$387.54M |
|
$387.54M |
|
$387.54M |
|
44.72M |
|
| Cash Flow Statement Financials | |
$-61.65M |
|
$46.27M |
|
$189.15M |
|
$49.35M |
|
$223.12M |
|
$173.77M |
|
$6.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
32.95 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-62.78M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.58% |
|
-5.58% |
|
-5.40% |
|
-5.58% |
|
$8.67 |
|
$-1.84 |
|
$-1.80 |
|